1. Home
  2. INKT vs MDCX Comparison

INKT vs MDCX Comparison

Compare INKT & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • MDCX
  • Stock Information
  • Founded
  • INKT 2017
  • MDCX 2008
  • Country
  • INKT United States
  • MDCX Canada
  • Employees
  • INKT N/A
  • MDCX N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • MDCX
  • Sector
  • INKT Health Care
  • MDCX
  • Exchange
  • INKT Nasdaq
  • MDCX Nasdaq
  • Market Cap
  • INKT 43.0M
  • MDCX 33.8M
  • IPO Year
  • INKT 2021
  • MDCX N/A
  • Fundamental
  • Price
  • INKT $11.10
  • MDCX $2.84
  • Analyst Decision
  • INKT Strong Buy
  • MDCX Strong Buy
  • Analyst Count
  • INKT 2
  • MDCX 1
  • Target Price
  • INKT $6.50
  • MDCX $10.00
  • AVG Volume (30 Days)
  • INKT 70.4K
  • MDCX 8.6K
  • Earning Date
  • INKT 03-20-2025
  • MDCX 01-01-0001
  • Dividend Yield
  • INKT N/A
  • MDCX N/A
  • EPS Growth
  • INKT N/A
  • MDCX N/A
  • EPS
  • INKT N/A
  • MDCX N/A
  • Revenue
  • INKT N/A
  • MDCX N/A
  • Revenue This Year
  • INKT N/A
  • MDCX N/A
  • Revenue Next Year
  • INKT N/A
  • MDCX N/A
  • P/E Ratio
  • INKT N/A
  • MDCX N/A
  • Revenue Growth
  • INKT N/A
  • MDCX N/A
  • 52 Week Low
  • INKT $4.56
  • MDCX $1.80
  • 52 Week High
  • INKT $19.00
  • MDCX $3.23
  • Technical
  • Relative Strength Index (RSI)
  • INKT 59.45
  • MDCX N/A
  • Support Level
  • INKT $7.32
  • MDCX N/A
  • Resistance Level
  • INKT $13.79
  • MDCX N/A
  • Average True Range (ATR)
  • INKT 2.06
  • MDCX 0.00
  • MACD
  • INKT 0.26
  • MDCX 0.00
  • Stochastic Oscillator
  • INKT 70.86
  • MDCX 0.00

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

About MDCX Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Share on Social Networks: